Aptuit and Laurus sign $100M JV accord

24 June 2007

USA-based Aptuit, which is focused on supporting the early drug development process, is to invest nearly $100.0 million in India's Laurus Labs. The deal, which sees Laurus chief executive Satyanarayana Chava join Aptuit's board, will establish the Aptuit Laurus joint venture.

The new entity, which will offer contract drug development, R&D and manufacturing facilities, will be based in Hyderabad, with additional sites in Vishakhapatnam and Bangalore. Further terms of the deal were not provided.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK







Today's issue

Company Spotlight